Regulatory advances in proteomics will be taking center stage at a Symposia scheduled to occur at the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting. The symposium entitled "Enabling Translational Proteomics with NCI's Clinical Proteomic Technologies for Cancer" is scheduled for July 25, 2011 at AACC's annual Meeting. The major focus of the symposia will be highlighting advances in understanding that have been made in understanding the Food and Drug Administration process of validating assays for usage and what investigators should know. This symposium is a continuation of previously signed Memorandum of Understanding between CPTC and AACC to join forces to promote and educate the clinical chemistry community in the area of proteomic standards and technology advances.
The American Association for Clinical Chemistry (AACC) is an international society comprised of medical professionals with an interest in clinical chemistry, clinical laboratory science, and laboratory medicine. Moreover, the organization represents a critical clinical insight importance in developing potential novel diagnostic from proteomics discoveries. The 2011 AACC Annual Meeting will be held in Atlanta, Georgia at the George World Congress Center from July 24 to 28. In addition to the symposium from CPTC, there will be informative sessions with regard to clinical chemistry and genomic medicine and several brown bag lunch sessions to discuss details of running specific assays. More information about the conference can be found at: http://www.aacc.org/events/2011am/pages/default.aspx.